A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Phase 2 Active not recruiting 120 enrolled Beijing Mabworks Biotech Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and ADA of MIL62 compared with placebo in participants with systemic lupus erythematosus.

Timeline

Start: 2023-05-26
Primary completion: 2026-02
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MIL62	Monoclonal antibody	1000 mg	Intravenous

A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Summary

Timeline

Drugs

Indications